7.50
Precedente Chiudi:
$7.55
Aprire:
$7.57
Volume 24 ore:
269.34K
Relative Volume:
0.88
Capitalizzazione di mercato:
$502.32M
Reddito:
$555.06M
Utile/perdita netta:
$-39.48M
Rapporto P/E:
-12.50
EPS:
-0.6
Flusso di cassa netto:
$29.05M
1 W Prestazione:
+4.31%
1M Prestazione:
+2.04%
6M Prestazione:
+13.29%
1 anno Prestazione:
-32.00%
Bioventus Inc Stock (BVS) Company Profile
Nome
Bioventus Inc
Settore
Industria
Telefono
(919) 474-6700
Indirizzo
4721 EMPEROR BOULEVARD, SUITE 100, DURHAM
Confronta BVS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
|
BVS
Bioventus Inc
|
7.50 | 505.67M | 555.06M | -39.48M | 29.05M | -0.60 |
|
ABT
Abbott Laboratories
|
128.47 | 218.16B | 43.84B | 13.90B | 6.92B | 7.9725 |
|
BSX
Boston Scientific Corp
|
92.19 | 137.24B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
355.31 | 135.41B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
98.57 | 128.03B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.38 | 48.21B | 5.88B | 1.34B | 799.60M | 2.3489 |
Bioventus Inc Stock (BVS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-12-17 | Aggiornamento | JP Morgan | Underweight → Neutral |
| 2023-12-07 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2023-08-09 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2022-11-22 | Downgrade | Craig Hallum | Buy → Hold |
| 2022-11-09 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2022-11-09 | Downgrade | JP Morgan | Overweight → Underweight |
| 2022-03-15 | Iniziato | Craig Hallum | Buy |
| 2021-11-15 | Ripresa | Morgan Stanley | Overweight |
| 2021-11-10 | Ripresa | JP Morgan | Overweight |
| 2021-07-01 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-08 | Iniziato | Canaccord Genuity | Buy |
| 2021-03-08 | Iniziato | Goldman | Buy |
| 2021-03-08 | Iniziato | JP Morgan | Overweight |
| 2021-03-08 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Bioventus Inc Borsa (BVS) Ultime notizie
(BVS) Price Dynamics and Execution-Aware Positioning - news.stocktradersdaily.com
Bioventus (NYSE:BVS) Director Sells $75,700.00 in Stock - MarketBeat
Divisadero Street Capital Management LP Decreases Stock Position in Bioventus Inc. $BVS - MarketBeat
Geode Capital Management LLC Has $6.98 Million Stake in Bioventus Inc. $BVS - Defense World
American Century Companies Inc. Grows Stock Holdings in Bioventus Inc. $BVS - Defense World
Buy Signal: Why Bioventus Inc stock is favored by top institutionsQuarterly Portfolio Summary & Fast Entry Momentum Trade Alerts - moha.gov.vn
HALPER SADEH LLC ENCOURAGES BIOVENTUS INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS - PR Newswire
Bioventus Inc. (BVS) Presents at Piper Sandler 37th Annual Healthcare ConferenceSlideshow - Seeking Alpha
Dir Nohra Files To Sell 10,000 Of Bioventus Inc [BVS] - TradingView
Is It Too Late To Consider Buying Bioventus Inc. (NASDAQ:BVS)? - Yahoo Finance
Will Bioventus Inc. stock reach Wall Street targetsTrade Exit Summary & Real-Time Market Sentiment Reports - Newser
Will Bioventus Inc. stock see insider buyingWeekly Stock Report & Short-Term High Return Ideas - Newser
(BVS) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Bioventus Reports Strong Q3 2025 Financial Performance - MSN
Bioventus: A New Start (NASDAQ:BVS) - Seeking Alpha
How Bioventus Inc. stock performs in weak economy2025 Top Gainers & Reliable Volume Spike Alerts - Newser
Bioventus (NASDAQ:BVS) Seems To Use Debt Quite Sensibly - 富途牛牛
Bioventus (NYSE:BVS) Trading Down 3.9%Here's What Happened - MarketBeat
Bioventus, Inc. Reports Strong Q3 Earnings Growth - MSN
Segall Bryant & Hamill LLC Purchases 232,302 Shares of Bioventus Inc. $BVS - MarketBeat
Bioventus to Present at the Piper Sandler 37th Annual Healthcare Conference - The Manila Times
[Form 3] Bioventus Inc. Initial Statement of Beneficial Ownership - Stock Titan
Bioventus (Nasdaq: BVS) to present at Piper Sandler 37th Healthcare Conference webcast - Stock Titan
Bioventus (NYSE:BVS) Shares Up 9.9%Time to Buy? - MarketBeat
Bioventus Appoints Ajay Dhankhar as New Director - MSN
Is Bioventus Inc. stock affected by interest rate hikesRisk Management & Weekly Chart Analysis and Guides - newser.com
Why Bioventus Inc. stock appeals to analystsJuly 2025 Decliners & Weekly Market Pulse Updates - newser.com
Is Bioventus Inc. stock attractive for income investorsMarket Trend Review & Risk Adjusted Buy and Sell Alerts - newser.com
Bioventus Inc. stock prediction for this weekDollar Strength & High Conviction Investment Ideas - newser.com
Smart tools for monitoring Bioventus Inc.’s price actionEarnings Beat & Technical Pattern Alert System - newser.com
Can Bioventus Inc. rally from current levelsJuly 2025 Catalysts & Community Trade Idea Sharing Platform - newser.com
Bioventus Inc. (BVS) Stock Forecast 2026, 2030 & 7-Year Price Prediction | Meyka AI - Meyka
Bioventus appoints Ajay Dhankhar to board as Class II director By Investing.com - Investing.com Australia
Bioventus appoints Ajay Dhankhar to board as Class II director - Investing.com
Bioventus Inc. Appoints Ajay Dhankhar to Board of Directors - TradingView
Bioventus Inc. Appoints Ajay Dhankhar to the Board as Class II Director, Effective November 14, 2025 - MarketScreener
[8-K] Bioventus Inc. Reports Material Event | BVS SEC FilingForm 8-K - Stock Titan
Bioventus Inc Azioni (BVS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):